180 Life Sciences Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 180 Life Sciences Corp. (the "Company") on February 26, 2024. The report details the implementation of a reverse stock split approved by stockholders on February 16, 2024, and filed with the Delaware Secretary of State on February 26, 2024. The Company is a biotechnology firm listed on the NASDAQ Capital Market under the symbols ATNF (Common Stock) and ATNFW (Warrants).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions regarding capital structure. The filing notes that the total outstanding shares of common stock will be reduced from approximately 11.3 million to approximately 0.6 million shares following the split.
Material Changes Versus Prior Period
- Reverse Stock Split: The Company executed a 1-for-19 reverse stock split, effective February 28, 2024, at 12:01 a.m. Eastern Time.
- Share Count Reduction: Issued and outstanding shares decreased from ~11.3 million to ~0.6 million.
- Equity Adjustments: Stock options, equity awards, and warrant exercise prices were adjusted proportionately (1-for-19 ratio) to maintain aggregate value. No fractional shares were issued; fractional interests were rounded up to the nearest whole share.
- Listing Compliance: The action was taken to regain compliance with NASDAQ Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company had received a deficiency letter on September 7, 2023, regarding non-compliance.
Guidance, Outlook, and Risks
Management Commentary: Management stated the primary objective of the reverse stock split is to satisfy the $1.00 minimum bid price requirement for continued listing on the NASDAQ Capital Market. The Company expects the closing bid price to increase above the $1.00 threshold post-split.
Risks and Contingencies: The filing notes that if the Company fails to regain compliance with the bid price requirement by the compliance date (March 5, 2024), it risks delisting. The filing also clarifies that the reverse split does not alter the par value, voting rights, or proportional ownership interests of stockholders, aside from minor rounding adjustments.
Key Facts for Investor Verification
- Effective Date: The reverse stock split becomes effective on February 28, 2024.
- Split Ratio: 1-for-19 (19 old shares convert to 1 new share).
- New CUSIP: 68236V302 (Trading symbols ATNF and ATNFW remain unchanged).
- Compliance Deadline: The Company must maintain a closing bid price of at least $1.00 for 10 consecutive business days before March 5, 2024, to avoid delisting proceedings.
- Fractional Shares: No cash is paid for fractional shares; they are rounded up to the nearest whole share.